Adult want real sex Stockholm NewJersey 7460

Added: Chinita Villalpando - Date: 08.12.2021 19:33 - Views: 47218 - Clicks: 6179

Study record managers: refer to the Data Element Definitions if submitting registration or information. Talk with your doctor and family members or friends about deciding to a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.

For general information, Learn About Clinical Studies. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or information. Search for terms x. Save this study. Warning You have reached the maximum of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. First Posted : December 26, Last Update Posted : December 26, Study Description. This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.

Drug Information available for: Dapagliflozin Dapagliflozin propanediol. FDA Resources. Arms and Interventions. Outcome Measures. Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials. More Information. Additional Information: CSP redacted. SAP redacted. Clin Cardiol. JAMA Cardiol. The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Epub Feb Epub Aug 3.

Epub Jan Diabetes Care. Epub Dec Epub Aug Lancet Diabetes Endocrinol. Epub Jun Erratum in: Lancet Diabetes Endocrinol. Epub Mar Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. Epub Nov Am Heart J. Epub Feb 7. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.

Am J Manag Care. Bloch MJ. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension. J Am Soc Hypertens. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. Epub May National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Drug: Dapagliflozin 10 mg Drug: Placebo tablet. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Actual Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :. Drug: Dapagliflozin 10 mg Oral dose od. Drug: Placebo tablet Oral dose od. Huntington Park, California, United States, Washington, District of Columbia, United States, Jacksonville Beach, Florida, United States, Arlington Heights, Illinois, United States, Burlington, North Carolina, United States, Philadelphia, Pennsylvania, United States, Sellersville, Pennsylvania, United States, Charleston, South Carolina, United States, Jeonju-si, Jeollabuk-do, Korea, Republic of, November 21, Key Record Dates.

Adult want real sex Stockholm NewJersey 7460

email: [email protected] - phone:(204) 233-9934 x 2263

Hot housewives searching real sex